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In mammals the methylation of cytosine
residues in DNA by DNA methyltransferases
(DNMTs) is the predominant postreplica-
tion base modification (Das and Singal
2004). Mammalian DNMTs transfer a
methyl group from S-adenosylmethionine
(SAM) to the C-5 position of cytosine within
CpG dinucleotides (Das and Singal 2004).
DNMTs found in mammalian cells include
DNMT1, DNMT3a, and DNMT3b (Okano
et al. 1998, 1999a). It is thought that
DNMTs function in either maintenance of
DNA methylation, where methylated CpG
sites on one DNA strand are copied, or in
de novo methylation, where both strands are
initially unmethylated and methylation at
novel sites is introduced (Das and Singal
2004). Specific forms of DNMT include
DNMT1, which is considered important for
maintenance and is constitutively expressed
in adult cells, and DNMT3a and 3b, which
have strong de novo activity (Das and Singal
2004) and are highly expressed in embryonic
cells (Okano et al. 1999b), presumably to
assist in methylation changes associated with
development. Defects in methylation of total
DNA or particular DNA sequences, includ-
ing hypomethylation and, conversely, hyper-
methylation, have been shown to be
associated with carcinogenesis, possibly as a
factor that facilitates aberrant under- or over-
expression of genes linked to cancer (Das and
Singal 2004). Aberrant methylation of pro-
moter regions resulting in inactivation of
human tumor suppressor gene expression has
been proposed to be an important mecha-
nism in cancer progression (Baylin et al.
1991). Understanding what modulates
changes in DNA methylation during malig-
nant transformation is a key issue in chemical
carcinogenesis. In this regard, during carcino-
genesis, global DNA hypomethylation
together with gene-speciﬁc hypermethylation,
often, but not always, occur. It is suspected
that DNMT1 underexpression causes the
total DNA hypomethylation, whereas over-
expression of DNMT3a or 3b induces gene-
specific promoter region hypermethylation
and quiescence of tumor suppressor genes
(Baylin et al. 1991; Chen et al. 2003). For
example, hypermethylation in the promoter
region and silencing of p16 tumor suppressor
gene are frequently observed during carcino-
genesis that can occur on a background of
global DNA hypomethylation (Wu et al.
2005). Cancer cells may be distinctive in that
DNMT1 alone is not responsible for main-
taining abnormal gene-speciﬁc hypermethyla-
tion, and both DNMTs 1 and 3b may
cooperate in this action (Rhee et al. 2000,
2002). However, the precise events that
account for changes in global or gene-speciﬁc
methylation patterns in carcinogenesis remain
uncertain.
Methylation changes occur during onco-
genic transformation with inorganic carcino-
gens such as arsenic, nickel, and cadmium
(Benbrahim-Tallaa et al. 2005; Salnikov and
Costa 2000; Takiguchi et al. 2003). For cad-
mium, a heavy metal classified as a human
carcinogen, human exposure is associated with
lung and possibly prostate cancer, whereas in
rodents the metal is clearly a prostate carcino-
gen (Waalkes 2003). In in vitro model systems
of carcinogenesis, cadmium exposure malig-
nantly transforms various human and rodent
cells, which give rise to aggressive cancers
when injected intomice (Achanzar et al. 2001;
Qu et al. 2005; Waalkes 2003). In particular,
cadmium induces malignant transformation
of the normal human prostate epithelial cell
line RWPE-1 (Achanzar et al. 2001), which
supports the potential for cadmium to directly
target this cell population in vivo. In this prior
work (Achanzar et al. 2001), to achieve malig-
nant transformation, control human prostate
epithelial RWPE-1 cells were exposed contin-
uously to 10 µM cadmium for 8 or more
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BACKGROUND: Aberrant DNA methylation is common in carcinogenesis. The typical pattern appears
to involve reduced expression of maintenance DNA methyltransferase, DNMT1, inducing genomic
hypomethylation, whereas increased expression of de novo DNMT3a or 3b causes gene-speciﬁc hyper-
methylation.
OBJECTIVES: During cadmium-induced malignant transformation, an unusual pattern of genomic
hypermethylation occurred that we studied to provide insight into the roles of speciﬁc DNMTs in
oncogenesis.
METHODS: Gene expression and DNA methylation were assessed in control and chronic cadmium-
transformed prostate epithelial cells (CTPE) using reverse transcription–polymerase chain reaction
(RT-PCR), Western blot analysis, methylation-speciﬁc PCR, and methyl acceptance assay.
RESULTS: During the 10-weeks of cadmium exposure that induced malignant transformation, pro-
gressive increases in generalized DNMT enzymatic activity occurred that were associated with over-
expression of DNMT3b without changes in DNMT1 expression. Increased DNMT3b expression
preceded increased DNMT enzymatic activity. Procainamide, a specific DNMT1 inhibitor,
reversed cadmium-induced genomic DNA hypermethylation. Reduced expression of the tumor
suppressor genes, RASSF1A and p16, began about the time DNMT3b overexpression ﬁrst occurred
and progressively decreased thereafter. RASSF1A and p16 promoter regions were heavily methy-
lated in CTPE cells, indicating silencing by hypermethylation, while the DNA demethylating
agent, 5-aza-2´-deoxycytidine, reversed this silencing. DNMT1 inhibition only modestly increased
RASSF1A and p16 expression in CTPE cells and did not completely reverse silencing.
CONCLUSIONS: These data indicate that DNMT3b overexpression can result in generalized DNA
hypermethylation and gene silencing but that DNMT1 is required to maintain these effects. The
pattern of genomic DNA hypermethylation together with up-regulation of DNMT3b may provide
a unique set of biomarkers to speciﬁcally identify cadmium-induced human prostate cancers.
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[Online 19 July 2007]weeks, a concentration near the estimated
range in the prostate of adult human males
with no known occupational exposure to cad-
mium. The cadmium-treated cells, designated
CTPE (cadmium-transformed prostate epithe-
lial cells), form malignant tumors after inocu-
lation into nude mice that morphologically
and biochemically resemble human prostatic
carcinoma (Achanzar et al. 2001). Thus, the
cadmium-transformed CTPE cells provide a
human model system in which to examine the
molecular events during cadmium carcino-
genesis in the prostate.
Previous work showed an unusual pattern
of enhanced generalized DNMT activity and
global DNA hypermethylation during cad-
mium induction of malignant transformation
in rat liver epithelial cells (Takiguchi et al.
2003). Thus, in the present study, we assessed
the impact of chronic cadmium exposure lead-
ing to acquisition of a malignant phenotype
on DNA methylation and DNMT activity in
a human cell model using CTPE cells.
Materials and Methods
Chemicals and reagents. Cadmium chloride
(CdCl2; purity 99%), 5-aza-2´-deoxycyti-
dine, and procainamide were purchased
from Sigma Chemical Co. (St. Louis, MO).
Keratinocyte serum-free medium (K-SFM),
epidermal growth factor (EGF), bovine
pituitary extract (BPE), 100 X antibiotic–
antimycotic mixture, and TRIzol reagent
were purchased from Life Technologies, Inc.
(Grand Island, NY). The mouse anti-p16 was
purchased from (Calbiochem, San Diego, CA).
The mouse anti-RASSF1A was purchased
from (Abcam, Cambridge, MA). The mouse
monoclonal anti-actin was purchased from
(Oncogene Research Products, Cambridge,
MA). The Bradford Protein Assay was 
purchased from Bio-Rad Laboratories
(Hercules, CA).
Cell culture and treatment. The non-
tumorigenic control (untransformed)
RWPE-1 cells were originally derived from
immortalized normal human prostate
epithelial cells and were grown as previously
described (Achanzar et al. 2001). Cells were
exposed continuously to 10 µM cadmium
chloride for up to 10 weeks. The cadmium-
transformed cells were designated CTPE
cells to distinguish them from the control
(untreated) RWPE-1 cells. Parallel cultures
grown in cadmium-free medium provided
passage-matched controls. CTPE cells pro-
duced aggressive carcinomas after inocula-
tion into nude mice, with morphologic and
molecular characteristics of prostate epithe-
lial carcinoma including prostate-specific
antigen (PSA) overexpression (Achanzar et
al. 2001). Control RWPE-1 cells did not
produce tumors upon inoculation (Achanzar
et al. 2001).
To evaluate p16 re-expression, we added
the demethylating agent 5-aza-2´-deoxy-
cytidine (0, 0.5, or 1 µM) to 50% conﬂuent
cell cultures. The cultures were dosed every
48 hr and harvested on day 6 for isolation of
proteins. Alternatively, in a time-course experi-
ment, 50% confluent cells were exposed to
1 µM 5-aza-2´-deoxycytidine for 0–6 hr.
Procainamide (0, 0.5, or 1 mM) was added to
50% conﬂuent cell cultures. The cultures were
dosed every 48 hr, then harvested after 96 hr
for isolation of proteins.
Global DNA methylation and DNMT
activity. The extent of global DNA methyla-
tion was determined by the methyl acceptance
using [3H]SAM and bacterial Sss1 DNA
methylase as previously described (Herman
et al. 1996). DNMT activity of cell lysates was
measured using the poly(dI.dC) poly(dI.dC)
double-stranded DNA as the substrate and
radiolabeled SAM as previously described
(Jeronimo et al. 2004).
RNA extraction and reverse transcription–
polymerase chain reaction (RT-PCR). Total
RNA was isolated using TRIzol reagent (Life
Technologies, Grand Island, NY). RT–PCR
was performed using a TITANIUM One-Step
RT-PCR kit (Clontech, San Jose, CA) and a
GeneAmp PCR system 9700 (Applied
Biosystems, Foster City, CA) according to the
kit’s instructions. Amplification conditions
were 60 min at 50°C and 5 min at 94°C fol-
lowed by 35 cycles for 1 min at 94°C, 1 min at
57°C, and 1 min at 72°C; 1 µg of total RNA
was used in each ampliﬁcation. Primers were
designed for DNMT1, DNMT3a, DNMT3b,
MBD2, and β-actin and were synthesized by
Invitrogen (Carlsbad, CA) as follows:
DNMT1 (gi: 6684524) (5´-ACCAAGCAA-
GAAGTGAAGCC-3´ and 5´-GCTTCCT-
GCAGAAGAACCTG-3´), product size:
366 bp; DNMT3a (gi:18033252) (5´-
CACACAGAAGCATATC
CAGGAGTG-3´ and 5´-AGTGACTGGGA
AACCAAATACCC-3´), product size: 551 bp;
DNMT3b (gi: 18033254) (5´-AATGT-
GAATCCAGCCAGGAAAGGC-3´and 5´-
ACTGGATTACACTCCAGGAACCGT-3´)
product size: 190 bp; β-actin (5´-AGAGATG-
GCCACGGCTGCTT-3´ and 5´-ATTTGC
GGTGGACGATGGAG-3´), product size:
460 bp. The level of β-actin was used to nor-
malize results.
Real-time RT-PCR analysis. Expression
levels of selected genes were quantiﬁed using
real-time RT-PCR analysis. In brief, total
RNA was extracted as described above, puri-
fied with RNeasy column and on-column
DNase I digestion (QIAGEN, Valencia, CA).
Purified total RNA was reverse-transcribed
with MuLV reverse transcriptaseand oligo-dT
primers. The forward and reverse primers
were synthetized by Invitrogen as fellows:
DNMT1 (5´-GGTTCTTCCTCCTGGA
GAATGTC-3´ and 5´-GGGCCACGCCG
TACTG-3´); DNMT3a (5´-AGGAAGCG
CAAGCACCC-3´ and 5´-ATTGGGTAA
TAGCTCTGAGGCG -3´); DNMT3b (5´-
CCAGCCCTGCGGCAG-3´ and 5´-GTTG
ACGAGGATCGAGTCTTCC-3´) and 18S
(gi: 337376) (5´-CGTTGATTAAGTCCCT
GCCCTT-3´ and 5´-TCAAGTTCGAC
CGTCTTCTCAG-3´). Quantitative assess-
ments of DNA amplification for each gene
were performed by a ﬂuorescence-based real-
time detection method (Bio-Rad Laboratories
GmbH, Munchen, Germany) and the iQ
SYBR Green Supermix. The dissociation
curve (melting curve) for each gene was per-
formed to verify the quality of the primers.
The standard curve for each gene was per-
formed to quantify the gene expression. Gene
expression was first normalized relative to
18S RNA within the same sample, and then
treatment group expression was calculated by
setting the control as 100%.
Western blot analysis. Total protein was
isolated and electrophoresed on NuPAGE
4–12% Bis-Tris gel and transferred to nitro-
cellulose membranes according to the manufac-
turer’s directions (Invitrogen). Immunoblotting
was performed using the human p16 antibody
(Calbiochem), the human RASSF1A antibody
(Abcam), and horseradish peroxidase-
conjugated anti-mouse secondary antibody
(Amersham, Piscataway, NJ).
Promoter region methylation of RASSF1A
and p16. DNA methylation in the CpG
islands of the p16 promoter region was deter-
mined by methylation-specific PCR (MSP).
MSP distinguishes unmethylated from
methylated alleles on the basis of sequence
changes produced after bisulﬁte treatment of
DNA, which converts unmethyled cytosine to
uracils, and subsequent PCR using primers
designed for either methylated or unmethy-
lated DNA (Balaghi and Wagner 1993). The
primers used were as follows: unmethylated
reaction 5´-TTTGGTTGGAGTGTGT
TAATGTG-3´ (sense) and 5´-CAAACCC
CACAAACTAAAAACAA-3´ (antisense) and
for the methylated reaction 5´-GTGTTAA
CGCGTTGCGTATC-3´ (sense) and 5´-
AACCCCGCGAACTAAAAACGA-3´ (anti-
sense) for RASSF1A and 5´-TTATTAGA
GGGTGGGGTGGATTGT-3´ (sense) and
5´-CCACCTAAATCAACCTCCAACCA-3´
(antisense) and for the methylatedreaction 5´-
TTATTAGAGGGTGGGGCGGATCGC
-3´ (sense) and 5´-CCACCTAAATCGA
CCTCCGACCG-3´ (antisense) for p16.
Statistical analysis. All data represent mean
± SE derived from three or more independent
experiments. Statistical signiﬁcance was deter-
mined by the Student t-test or by analysis of
variance followed by Dunnett’s multiple com-
parison test as appropriate. A p ≤ 0.05 was con-
sidered statistically signiﬁcant in all cases.
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DNA methyltransferases activity and expression
and total DNA methylation during cadmium-
induced malignant transformation. Chronic
cadmium exposure of human prostate epithe-
lial cells led to a signiﬁcant increase in global
DNA methylation concurrently with transfor-
mation, as evidenced by a 53% decrease in
unmethylated sites in DNA in the CTPE cells.
Increased methylation occurred prior to 
cadmium-induced transformation (Figure 1A),
clearly indicating that DNA methylation errors
occurred during the process of cadmium-
induced malignant transformation.
Generalized DNMT enzymatic activity
also exhibited a remarkable increase during
cadmium-induced malignant transforma-
tion (Figure 1B). Enzymatic activity of
DNMT increased up to 220% in CTPE
cells compared with control cells. Transcript
levels of the various DNMT isoforms showed
no signiﬁcant changes in CTPE cells with the
single exception of the de novo DNMT3b,
which increased nearly 3-fold (Figure 2).
The time course for DNMT3b expression
showed a gradual, time-dependent, progres-
sive increase during cadmium transformation
(Figure 3). The increased expression of
DNMT3b was signiﬁcant at 4 weeks of cad-
mium exposure. A similar time-course assess-
ment for DNMT1and DNMT3a expression
indicated that no signiﬁcant changes occurred
during cadmium-induced acquisition of
malignant phenotype.
Expression and promoter methylation of
tumor suppressor genes RASSF1A and
p16 during cadmium-induced malignant
transformation. The expression of tumor
suppressor genes RASSF1A and p16 was pro-
gressively reduced during cadmium exposure
(Figure 4A). The inhibition of RASSF1A
expression was an early event that started by
2 weeks of cadmium exposure, whereas the
inhibition of p16 started by 6 weeks of cad-
mium exposure, which is soon after
DNMT3b expression increases became sig-
niﬁcant (Figure 3).
To study the mechanism of cadmium-
induced RASSF1A and p16 quiescence in
CTPE cells, we assessed promoter region
methylation. CpG islands in the RASSF1A
and p16 promoter were clearly hypermethy-
lated compared with control in CTPE cells
(Figure 4B). This hypermethylation likely
accounts for cadmium-induced silencing of
these important tumor suppressor genes. In
fact, when CTPE cells were treated with the
DNA demethylating agent, 5-aza-2´-deoxy-
cytidine, it effectively reversed the loss of
RASSF1A and p16 expression that occurred
during cadmium transformation (Fig. 5A).
Time-course analysis indicated that 5-aza-2´-
deoxycytidine (1 µM) increased RASSF1A
protein expression nearly 2.4-fold (p < 0.05)
and p16 about 2-fold (p < 0.05) after 96 hr of
treatment (Figure 5B).
Effect of procainamide on global DNA
methylation and RASSF1A and p16 expression
in control and CTPE cells. The treatment with
procainamide, a speciﬁc DNMT1 inhibitor,
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Figure 1. Global DNA methylation status and DNA methyltransferase activity during cadmium transformation
of human prostate epithelial cells. Cells were grown in the presence or absence of 10 µM of cadmium for up
to 10 weeks. (A) DNA methylation in control and exposed cells was determined by the in vitro methyl accep-
tance capacity of DNA using [3H-methyl]SAM as a methyl donor and a prokaryotic CpG DNA methyltrans-
ferase as described in “Materials and Methods.” Arrows indicate the ability of cells to form tumors upon
inoculation into Nude mice according our prior work (Achanzar et al. 2001). (B) DNA methyltransferase
activity was assayed as described in “Materials and Methods.” Data represent mean ± SE (n = 3).
*Signiﬁcantly different from control.
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Figure 2. DNMT isoform transcript levels during cadmium exposure in CTPE cells. Transcript levels of speciﬁc
forms of DNMT were assessed in control and CTPE cells exposed for 10 weeks to cadmium. RNA was isolated
and subjected to RT-PCR analysis using a set of primers designed to amplify DNMT1, DNMT3a, DNMT3b, and
β-actin transcripts. PCR products were separated on a 1.7% agarose gel. Densitometric data are given as
percent of control (A) and normalized to β-actin (B) and expressed as mean ± SE (n = 3). 
*Signiﬁcantly different from control.
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Figure 3. Analysis of the effect of chronic cadmium
exposure of prostate epithelial cells on DNMT3b and
DNMT1 mRNA expression. Cells were grown in the
presence or absence of 10 µM cadmium for up to
10 weeks. RNA was isolated and subjected to real-time
RT-PCR analysis using a set of primers designed to
amplify DNMT3b, DNMT1, and 18S gene products. PCR
products were separated on a 1.7% agarose gel.
Densitometric data are given as percent of control and
expressed as mean ± SE (n= 3).
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*caused a clear increase in unmethylated DNA
content to above control levels, indicating that
DNMT1 plays a key role in maintaining the
aberrant genomic methylation pattern
acquired during cadmium-induced malignant
transformation in human prostate epithelial
cells (Figure 6A).
DNMT1 inhibition only modestly
increased both RASSF1A (23%) (Figure 6B)
and p16 (28%) (Figure 6C) expression at the
protein level in CTPE cells. Although pro-
cainamide induced increases in RASSF1A and
p16 expression in CTPE cells, their expression
was still well below control levels, indicating
that DNMT1 is only partially responsible for
maintaining gene-specific promoter region
hypermethylation.
Discussion
The present work indicates that DNA hyper-
methylation at the global and gene-specific 
levels occurred in association with cadmium-
induced malignant transformation of human
prostate epithelial cells. This total and gene-
speciﬁc hypermethylation is associated with an
overexpression of DNMT3b without changes
in DNMT1 expression. Increased expression of
DNMT3b in CTPE cells occurred as an early
event in response to chronic cadmium expo-
sure, and, importantly, in advance of malig-
nant transformation. Exactly how cadmium
leads to the transcriptional up-regulation of the
DNMT3b gene is unclear. The de novo
DNMTs, such as 3b, are thought to be critical
in tumor suppressor gene silencing by pro-
moter region hypermethylation. For example,
both RASSF1A and p16 are frequently inacti-
vated in human malignancies by methylation
changes during malignant conversion
(Auerkari 2006; Baylin et al. 1991; Kuzmin
et al. 2002; Perry et al. 2006; Wu et al. 2005).
Thus, the increase in DNMT3b expression
seen in CTPE cells likely accounts for the pro-
gressive silencing of RASSF1A and p16, which
was reversible after treatment with a general
DNA demethylating agent. Our data also
indicated that DNMT1 was critical in main-
taining this aberrant total DNA methylation
level, but probably had much less impact on
gene-speciﬁc hypermethylation. Similarly, rat
liver cells chronically treated with cadmium
show global DNA hypermethylation and
increased overall DNMT enzyme activity
during malignant transformation (Takiguchi
et al. 2003). Hence, the occurrence of global
DNA hypermethylation appears to be a con-
sistent finding in cadmium-induced malig-
nant conversion. Thus, the deregulation of
Cadmium transformation and tumor suppressor loss
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Figure 4. Expression and promoter region methyla-
tion status of p16 and RASSF1A during chronic cad-
mium exposure. Cells were grown in the presence or
absence of 10 µM cadmium for up to 10 weeks. (A)
Proteins were isolated and subjected to Western
blot analysis using antibodies against p16, RASSF1A,
and β-actin. Blots were analyzed densitometrically,
normalized to β-actin, and expressed as percent of
control. (B) Methylation of the p16 and RASSF1A pro-
moter regions determined by MSP. The presence of
visible PCR product in lanes marked “U” indicates
the unmethylated genes, whereas the presence of
product in lanes marked “M” indicates the methy-
lated gene. The source of DNA is indicated above
each lane. CpGENOME universal methylated DNA
(CHEMICON International, Inc., Temecula, CA) was
used as a positive control.
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Figure 5. Effect of a demethylating agent 5-aza-2´-deoxycytydine on p16 and RASSF1A protein expression.
(A) CTPE cells were grown in the presence or absence of 0.5 or 1 µM of 5-aza-2´-deoxycytydine for 6 days.
(B) CTPE cells were grown in presence or absence of 1 µM of 5-aza-2´-deoxycytydine over 96 hr. Proteins
were isolated and subjected to Western blot analysis using antibodies against p16, RASSF1A and β-actin.
Blots were analyzed densitometrically, normalized to β-actin, and expressed as percent of control. Data
represent mean ± SE(n = 3). 
*Signiﬁcantly different from control.
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Figure 6. DNA methylation status, p16 and RASSFA1 protein expression after exposure to procainamide in
CTPE cells. CTPE cells were grown in the presence or absence of 0.5 mM procainamide over 96 hr. (A) DNA
methylation in control and CTPE cells was determined by the in vitro methyl acceptance capacity of DNA
using [3H-methyl]SAM as a methyl donor and a prokaryotic CpG DNA methyltransferase as described in
“Materials and Methods.” Proteins were isolated and subjected to Western blot analysis using antibodies
against (B) RASSF1A and p16, and β-actin. Blots were analyzed densitometrically and normalized to
β-actin. Data represent mean ± SE(n = 3). 
*Signiﬁcantly different from control.
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B CDNMT3b in CTPE cells occurred before the
characteristics of malignant transformation
were detectable and may account for the
acquisition of malignant phenotype as well as
the silencing of the tumor suppressor genes,
RASSF1A and p16.
The exact mechanism behind oncogenic
changes in locus-specific and global DNA
methylation in human cells is unclear.
DNMT1 expression showed no changes during
cadmium transformation. However, our data
indicates DNMT1 activity was critical to the
maintenance of cadmium-induced aberrant
global DNA hypermethylation. Human cancer
cells differ in their reliance on DNMT1 for
maintaining DNA methylation (Rhee et al.
2000a; Ting et al. 2006), but it is clearly
required to maintain the aberrant DNA methy-
lation in CTPE cells. Treatment with pro-
cainamide, a specific DNMT1 inhibitor,
completely reversed cadmium-induced global
DNA hypermethylation. DNMT1 inhibition
did not, however fully restore the cadmium-
induced loss of RASSF1A and p16 expression,
indicating that DNMT1 is only partially
required for maintaining locus-speciﬁc changes
in methylation in CTPE cells. Thus DNMT1,
although not overexpressed, apparently acts in
cooperation with DNMT3b. This is consistent
with what is observed in human colorectal car-
cinoma cells, which appear to require both
DNMT1 and DNMT3b expression to retain
p16 silencing via promoter region hyper-
methylation (Baylin et al. 1998). In addition,
over-expression of DNMT3b, but not
DNMT1 and DNMT3a, is common in vari-
ous cancer cells (Girault et al. 2003; Robertson
et al. 1999; Saito et al. 2002), suggesting that
DNMT3b plays an important role in the devel-
opment of aberrant promoter methylation dur-
ing oncogenesis. Thus, even though DNMT1
expression is unaltered in CTPE cells, it appears
to be required for maintenance of aberrant
global DNA hypermethylation, and, to a lesser
extent, at the locus-speciﬁc level.
Several studies indicate that DNA hyper-
methylation is an important mechanism in
prostate cancer initiation and progression.
Studies indicate more than 30 genes can
undergo aberrant hypermethylation in prostate
cancer (Li et al. 2004; 2005). These include
tumor-suppressor genes, such as RASSF1A and
p16, as well as genes involved in a number of
key cellular pathways like hormonal response,
cell cycle control, and tumor-cell invasion
(Jeronimo et al. 2004). For many of these
genes, promoter hypermethylation is often the
main mechanism underlying their functional
loss in prostate cancer (Jeronimo et al. 2004; Li
et al. 2004, 2005). Indeed RASSF1A and p16
silencing in CTPE cells was reversed by the
DNA demethylating pyrimidine analog
5-aza-2´-deoxycytidine in the present study.
Inappropriate silencing of genes in prostatic
epithelial cells may contribute to all stages of
cancer development, including initiation, pro-
gression, invasion, and metastasis. In fact,
hypermethylation-based gene silencing has
been correlated with acquisition of androgen
independence in advanced prostate cancer
(Jeronimo et al. 2004). Tumors showing
acquired androgen independence are usually
much more aggressive and frequently fatal
(Jeronimo et al. 2004). Our work also indicates
that during cadmium-induced transformation,
CTPE cells acquire androgen independence
(Benbrahim-Tallaa et al. 2007), and the
propensity for cadmium to induce DNA
hypermethylation may contribute to this con-
version. An insidious but common environ-
mental pollutant like cadmium that could
potentially drive human prostate cancer pro-
gression to a more lethal phenotype deserves
further study.
DNMT3b is frequently overexpressed 
in tumor cells and its expression has been
correlated with decreasing differentiation
(Robertson et al. 1999). It is suspected that
DNMT3b is at least partially responsible for
the aberrant methylation observed in cancer
cells and that it is required for the active sup-
pression of genes (Beaulieu et al. 2002; Jin
et al. 2005; Lin et al. 2005). However,
although DNMT3b is generally considered a
de novo DNMT that can methylate DNA at
novel sites, it may also be critical for the main-
tenance of global DNA methylation (Beaulieu
et al. 2002; Chen et al. 2003; Jin et al. 2005;
Lin et al. 2005). The results of the present
study indicate DNMT3b and DNMT1 coop-
eratively maintain cadmium-induced aberrant
DNA methylation and gene silencing in
malignantly transformed CTPE cells.
However, defining the mechanisms of cad-
mium-induced DNMT3b overexpression and
the precise role of DNMT3b in DNA hyper-
methylation will require further research.
In summary, the present work demon-
strates that overexpression of DNMT3b was
associated with cadmium-induced malignant
transformation in human prostate epithelial
cells and caused genomewide and gene-speciﬁc
DNA hypermethylation in association with
DNMT1. DNMT3b overexpression occurred
contemporaneously with global DNA hyper-
methylation and tumor suppressor gene silenc-
ing through increased promoter region
methylation. Finally, the pattern of genome-
wide hypermethylation and DNMT3b over-
expression combined with tissue cadmium
levels may provide biomarkers to speciﬁcally
identify cadmium-induced human prostate
cancers.
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